Vol 3 (December 25, 2025): AME Clinical Trials Review

Linvoseltamab, a new BCMA-targeting bispecific antibody for multiple myeloma: linking new with existing data

Challenging the status quo: ivonescimab’s bid to displace anti-PD-(L)1 inhibitors

PEARL trial: efficacy and challenges of durvalumab monotherapy in metastatic non-small cell lung cancer with PD-L1 expression of ≥25%

Recent developments in HER2-targeted therapy for patients with HER2-positive metastatic breast cancer: insights from the latest DESTINY-Breast12 trial results

Beyond the surface: the hidden aggression of visceral pleural invasion in early-stage non-small cell lung cancer

Insights into long-term safety and efficacy of evinacumab in homozygous familial hypercholesterolaemia

Third- and later-line systemic therapy in metastatic gastric cancer: a persistent unmet need

Six-year results of the CLL14 study—redefining long-term outcomes in chronic lymphocytic leukemia management

Breaking through complexity: the expanding role of optical coherence tomography in PCI of complex coronary lesions

Optimizing the adjuvant chemotherapy for HER2-positive early breast cancer

Should we not use neurokinin-1 receptor antagonists in the prevention of trastuzumab deruxtecan-induced nausea and vomiting?—Putting the results of the ERICA study into perspective

Epcoritamab: the next frontier in the treatment of relapsed/refractory follicular lymphoma